Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
IQ-AI Limited specializes in advanced healthcare information services, leveraging artificial intelligence to enhance medical imaging and diagnostics. The company operates primarily in the UK and has developed proprietary software solutions that improve the accuracy and efficiency of radiological assessments, setting it apart from traditional diagnostic methods.
IQ-AI generates revenue primarily through software licensing agreements with healthcare providers, allowing them to utilize its AI-driven diagnostic tools. The company benefits from high gross margins due to low variable costs associated with software distribution and has a competitive edge through its proprietary algorithms that enhance diagnostic accuracy.
Adoption rates of AI in medical imaging within the UK healthcare system
Partnerships with major healthcare providers for software integration
Regulatory approvals for new AI diagnostic tools
Market expansion into European and North American healthcare markets
Regulatory changes affecting AI in healthcare could limit operational capabilities.
Technological disruption from competitors developing superior AI diagnostic tools.
Emerging AI startups offering similar or better diagnostic solutions at lower costs.
Established healthcare IT companies entering the AI diagnostic space.
Negative cash flow could limit operational flexibility and growth initiatives.
moderate - The demand for healthcare services is generally stable, but economic downturns can impact healthcare spending.
Minimal impact as the company has no debt; however, higher rates could affect the funding available for healthcare providers to invest in new technologies.
minimal - The company operates without debt, reducing exposure to credit market fluctuations.
growth - Investors looking for high-growth potential in the healthcare technology sector.
high - The stock has exhibited significant price fluctuations, evidenced by a 43.1% decline over the last six months.